tacrolimus
tacrolimus: sourced relationships with 1 company · 42 clinical trials tracked · 1 FDA decision.
tacrolimus evidence translation
What we can confirm
1 FDA record · 42 tracked trials
What it means
What to watch
Prepared research question
How could tacrolimus → RDY affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 7 study sponsors
Related indications
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| DR REDDYS LABORATORIES LTD (RDY) Reported 2010-05-12 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (42)showing 10 most recent
A Multicenter, Phase 3 Randomized, Active-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Tegoprubart Compared With Tacrolimus in Adult Participants Undergoing De Novo Kidney Transplantation
Primary endpoint: Efficacy failure rate at 12 months post-transplant, defined as the first occurrence of biopsy proven acute rejection, graft loss, or death
A Phase 3 Randomized, Open-Label Multicenter Study to Evaluate Efficacy and Safety of Inebilizumab in Adult Participants With Primary Membranous Nephropathy (PMN)
Primary endpoint: Percentage of Participants Achieving Complete Remission at Week 104
Pilot Study of Emapalumab With Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis for Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation
Primary endpoint: Incidence of grade 3 or higher adverse events (AEs)
A Phase I Study to Evaluate the Safety of Ruxolitinib in Combination With Azacitidine Maintenance in Patients Undergoing Reduced Intensity Allogeneic Transplant for Acute Myeloid Leukemia (AML)
Primary endpoint: Incidence of dose limiting toxicities (DLTs)
A Seamless Phase 2/3 Randomized, Open-label Study to Investigate Efficacy and Safety of Frexalimab Versus Tacrolimus in Adult Kidney Transplant Recipients
Primary endpoint: Composite efficacy failure rate (BPAR, graft loss, and death) by 1 year post kidney transplantation
Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical Treatment of Atopic Dermatitis
Primary endpoint: ≥50% Change in SCORAD score (SCORing Atopic Dermatitis)from baseline at 8 weeks with minimum score of 0 and maximum score of 103 ; higher score indicating more severe disease and lower score indicating better disease control.
Peri-Hematopoietic Cell Transplantation Ruxolitinib in Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
Primary endpoint: Incidence of grade II-IV graft versus host disease (GVHD) requiring systemic immune suppression
Randomized Pilot Study of Ruxolitinib for Switch-Maintenance Prophylaxis of Graft-versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation After Intermediate-Dose Post-Transplant Cyclophosphamide (Rux Switch-Maintenance in Intermediate PTCY: RuSMa-PTCY) in Comparison to Full-Dose PTCY
Primary endpoint: assess cGVHD-free survival
An Open Label, Non-Randomized, Multi-Center Pilot Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for GVHD Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
Primary endpoint: Severe acute GVHD-free Survival (SGFS)
A Phase 2 Study of Fludarabine and Intermediate-dose Total Body Irradiation (800 cGy) Followed by Post-transplant Cyclophosphamide in Patients Aged 18-65 Undergoing Allogeneic Stem Cell Transplant for Hematologic Malignancies
Primary endpoint: Overall survival (OS) at 1-year following treatment with fludarabine plus intermediate-dose total body irradiation (TBI 800 cGy) with post-transplant cyclophosphamide (PTCy)
Frequently asked questions
Which companies have sourced relationships with tacrolimus?
tacrolimus has dated SEC/FDA relationship records for DR REDDYS LABORATORIES LTD.
How many clinical trials involve tacrolimus?
BioSniper tracks 42 clinical trials involving tacrolimus.
What is tacrolimus's latest FDA decision?
The most recent tracked FDA decision for tacrolimus is Approval, dated May 12, 2010.